Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Diethylpropion Hydrochloride
Overview
What is Diethylpropion HydrochlorideER?
Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are available for oral administration as extended release tablets containing 75 mg diethylpropion hydrochloride, USP. The inactive ingredients in each extended release tablet are: mannitol, carbomer homopolymer, tartaric acid, hydroxypropyl methylcellulose, povidone, and magnesium stearate.
Diethylpropion hydrochloride is a sympathomimetic agent. The chemical name for diethylpropion hydrochloride is 1-phenyl-2-diethyl-amino-1-propanone hydrochloride.
Its chemical structure is:
In diethylpropion hydrochloride extended release tablets, 75 mg, diethylpropion hydrochloride is dispersed in a hydrophilic matrix. On exposure to water, the diethylpropion hydrochloride is released at a relatively uniform rate as a result of slow hydration of the matrix. The result is controlled release of the anorectic agent.
What does Diethylpropion HydrochlorideER look like?
What are the available doses of Diethylpropion HydrochlorideER?
Sorry No records found.
What should I talk to my health care provider before I take Diethylpropion HydrochlorideER?
Sorry No records found
How should I use Diethylpropion HydrochlorideER?
Diethylpropion hydrochloride extended release tablets, 75 mg are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of BMI based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds divided by 2.2 = kg; inches x 0.0254 = meters.
The usefulness of agents of this class (see ) should be measured against possible risk factors inherent in their use such as those described below. Diethylpropion hydrochloride extended release tablets, 75 mg are indicated for use as monotherapy only.
Diethylpropion Hydrochloride Extended Release Tablets, 75 mg:
One extended-release 75 mg tablet daily, swallowed whole, in midmorning.
Geriatric use
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See , .)
What interacts with Diethylpropion HydrochlorideER?
Pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension. (See ).
Agitated states.
Patients with a history of drug abuse.
Use in combination with other anorectic agents is contraindicated.
During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result.
What are the warnings of Diethylpropion HydrochlorideER?
Significant bleeding can result from aspirin therapy in patients with peptic ulcer or other gastrointestinal lesions, and in patients with bleeding disorders. Aspirin administered preoperatively may prolong the bleeding time. Butalbital is habit-forming and potentially abusable. Consequently, the extended use of Butalbital, Aspirin, and Caffeine Capsules, USP is not recommended. Results from epidemiologic studies indicate an association between aspirin and Reye’s Syndrome. Caution should be used in administering this product to children, including teenagers, with chicken pox or flu.
The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension. Under these circumstances, diethylpropion hydrochloride extended release tablets, 75 mg should be immediately discontinued, and the patient should be evaluated for the possible presence of pulmonary hypertension.
To limit unwarranted exposure and risks, treatment with diethylpropion hydrochloride extended release tablets, 75 mg should be continued only if the patient has satisfactory weight loss within the first 4 weeks of treatment (e.g., weight loss of at least 4 pounds, or as determined by the physician and patient).
Diethylpropion hydrochloride extended release tablets, 75 mg are not recommended for patients who used any anorectic agents within the prior year.
If tolerance develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued. Diethylpropion hydrochloride extended release tablets, 75 mg may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.
Prolonged use of diethylpropion hydrochloride may induce dependence with withdrawal syndrome on cessation of therapy. Hallucinations have occurred rarely following high doses of the drug. Several cases of toxic psychosis have been reported following the excessive use of the drug and some have been reported in which the recommended dose appears not to have been exceeded. Psychosis abated after the drug was discontinued. When central nervous system active agents are used, consideration must always be given to the possibility of adverse interactions with alcohol.
What are the precautions of Diethylpropion HydrochlorideER?
General
Caution is to be exercised in prescribing diethylpropion hydrochloride extended release tablets, 75 mg for patients with hypertension or with symptomatic cardiovascular disease, including arrhythmias. Diethylpropion hydrochloride extended release tablets, 75 mg should not be administered to patients with severe hypertension.
Reports suggest that diethylpropion hydrochloride may increase convulsions in some epileptics. Therefore, epileptics receiving diethylpropion hydrochloride extended release tablets, 75 mg should be carefully monitored. Titration of dose or discontinuance of diethylpropion hydrochloride extended release tablets, 75 mg may be necessary.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
Information for Patient
The patient should be cautioned about concomitant use of alcohol or other CNS-active drugs and diethylpropion hydrochloride extended release tablets, 75 mg (See .) The patient should be advised to observe caution when driving or engaging in any potentially hazardous activity.
Laboratory Tests
None
Drug Interactions
Because diethylpropion hydrochloride extended release tablets, 75 mg are monoamines, hypertension may result when either agent is used with monoamine oxidase (MAO) inhibitors (See ).
Efficacy of diethylpropion with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems; therefore, the concomitant use with other anorectic agents is contraindicated.
Antidiabetic drug requirements (i.e., insulin) may be altered. Concurrent use with general anesthetics may result in arrhythmias. The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
No long-term animal studies have been done to evaluate diethylpropion hydrochloride for carcinogenicity. Mutagenicity studies have not been conducted. Animal reproduction studies have revealed no evidence of impairment of fertility (see ).
Pregnancy
Teratogenic Effects
Non-Teratogenic Effects
Abuse with diethylpropion hydrochloride during pregnancy may result in withdrawal symptoms in the human neonate.
Nursing Mothers
Since diethylpropion hydrochloride and/or its metabolites have been shown to be excreted in human milk, caution should be exercised when diethylpropion hydrochloride extended release tablets, 75 mg are administered to a nursing woman.
Geriatric Use
Clinical studies of diethylpropion hydrochloride extended release tablets, 75 mg did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Pediatric Use
Since safety and effectiveness in pediatric patients below the age of 16 have not been established, diethylpropion hydrochloride extended release tablets, 75 mg is recommended for use in pediatric patients 16 years of age and under.
What are the side effects of Diethylpropion HydrochlorideER?
Cardiovascular:
Central Nervous System:
Gastrointestinal:
Allergic:
Endocrine:
Hematopoietic System:
Miscellaneous:
What should I look out for while using Diethylpropion HydrochlorideER?
Pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension. (See ).
Agitated states.
Patients with a history of drug abuse.
Use in combination with other anorectic agents is contraindicated.
During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result.
Diethylpropion hydrochloride extended release tablets, 75 mg should not be used in
combination with other anorectic agents, including prescribed drugs, over-the-counter preparations, and herbal products.
In a case-control epidemiological study, the use of anorectic agents, including diethylpropion, was associated with an increased risk of developing pulmonary
hypertension, a rare, but often fatal disorder. The use of anorectic agents for longer
than 3 months was associated with a 23-fold increase in the risk of developing
pulmonary hypertension. Increased risk of pulmonary hypertension with repeated
courses of therapy cannot be excluded.
The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension. Under these circumstances, diethylpropion hydrochloride extended release tablets, 75 mg should be immediately discontinued, and the patient should be evaluated for the possible presence of pulmonary hypertension.
Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine has been reported. Possible contributing factors
include use for extended periods of time, higher than recommended dose, and/or use
in combination with other anorectic drugs. Valvulopathy has been very rarely reported
with diethylpropion hydrochloride extended release tablets, 75 mg monotherapy, but
the causal relationship remains uncertain.
To limit unwarranted exposure and risks, treatment with diethylpropion hydrochloride extended release tablets, 75 mg should be continued only if the patient has satisfactory weight loss within the first 4 weeks of treatment (e.g., weight loss of at least 4 pounds, or as determined by the physician and patient).
Diethylpropion hydrochloride extended release tablets, 75 mg are not recommended for patients who used any anorectic agents within the prior year.
If tolerance develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued. Diethylpropion hydrochloride extended release tablets, 75 mg may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.
Prolonged use of diethylpropion hydrochloride may induce dependence with withdrawal syndrome on cessation of therapy. Hallucinations have occurred rarely following high doses of the drug. Several cases of toxic psychosis have been reported following the excessive use of the drug and some have been reported in which the recommended dose appears not to have been exceeded. Psychosis abated after the drug was discontinued. When central nervous system active agents are used, consideration must always be given to the possibility of adverse interactions with alcohol.
What might happen if I take too much Diethylpropion HydrochlorideER?
Manifestations of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, and mydriasis.
Fatigue and depression usually follow the central stimulation.
Cardiovascular effects include tachycardia, arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Overdose of pharmacologically similar compounds has resulted in convulsions, coma and death.
The reported oral LD for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg.
Management of acute diethylpropion hydrochloride intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Intravenous phentolamine has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates diethylpropion hydrochloride extended release tablets, 75 mg overdosage.
How should I store and handle Diethylpropion HydrochlorideER?
Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature).Dispense in a tight, light-resistant container.Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature).Dispense in a tight, light-resistant container.Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are supplied in bottles of 7 (NDC 33261-0354-07), 14 (NDC 33261-0354-14), 28 (NDC 33261-0354-28) and 30 (NDC 33261-0354-30).Each white to off-white capsule-shaped tablet is debossed “LCI” on one side and “1477” on the other side.Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].Keep tightly closed and protect from excessive heat.Manufactured by:Lannett Company, Inc.Philadelphia, PA 19136Made in the USARepackaged By :Aidarex Pharmaceuticals LLC,Corona, CA 92880Rev. 09/1010-598
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Actions include some central nervous system stimulation and elevation of blood pressure. Tolerance has been demonstrated with all drugs of this class in which these phenomena have been looked for.
Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. For example, other central nervous system actions or metabolic effects may be involved.
Adult obese subjects instructed in dietary management and treated with "anorectic" drugs lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials.
The magnitude of increased weight loss of drug-treated patients over placebo-treated patients averages some fraction of a pound a week. However, individual weight loss may vary substantially from patient to patient. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an "anorectic" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician/investigator relationship, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.
The natural history of obesity is measured in years, whereas most studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone is unknown.
Diethylpropion is rapidly absorbed from the GI tract after oral administration and is extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Many of these metabolites are biologically active and may participate in the therapeutic action of diethylpropion hydrochloride extended release tablets, 75 mg. Due to the varying lipid solubilities of these metabolites, their circulating levels are affected by urinary pH. Diethylpropion and/or its active metabolites are believed to cross the blood-brain barrier and the placenta.
Diethylpropion and its metabolites are excreted mainly by the kidney. It has been reported that between 75-106% of the dose is recovered in the urine within 48 hours after dosing. Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.
The controlled-release characteristics of diethylpropion hydrochloride extended release tablets, 75 mg have been demonstrated by studies in humans in which plasma levels of diethylpropion-related materials were measured by phosphorescence analysis. Plasma levels obtained with the diethylpropion hydrochloride extended release tablets, 75 mg formulation administered once daily indicated a more gradual release than the immediate-release formulation (three 25 mg tablets given in a single dose).
Diethylpropion hydrochloride extended release tablets, 75 mg have not been shown superior in effectiveness to the same dosage of the immediate-release formulation (one 25 mg tablet three times daily). After administration of a single dose of diethylpropion hydrochloride extended release tablets, 75 mg (one 75 mg extended release tablet) or diethylpropion hydrochloride solution (75 mg dose) in a cross-over study using normal human subjects, the amount of parent compound and its active metabolites recovered in the urine within 48 hours for the two dosage forms were not statistically different.
Non-Clinical Toxicology
Pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension. (See ).Agitated states.
Patients with a history of drug abuse.
Use in combination with other anorectic agents is contraindicated.
During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result.
Diethylpropion hydrochloride extended release tablets, 75 mg should not be used in
combination with other anorectic agents, including prescribed drugs, over-the-counter preparations, and herbal products.
In a case-control epidemiological study, the use of anorectic agents, including diethylpropion, was associated with an increased risk of developing pulmonary
hypertension, a rare, but often fatal disorder. The use of anorectic agents for longer
than 3 months was associated with a 23-fold increase in the risk of developing
pulmonary hypertension. Increased risk of pulmonary hypertension with repeated
courses of therapy cannot be excluded.
The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension. Under these circumstances, diethylpropion hydrochloride extended release tablets, 75 mg should be immediately discontinued, and the patient should be evaluated for the possible presence of pulmonary hypertension.
Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine has been reported. Possible contributing factors
include use for extended periods of time, higher than recommended dose, and/or use
in combination with other anorectic drugs. Valvulopathy has been very rarely reported
with diethylpropion hydrochloride extended release tablets, 75 mg monotherapy, but
the causal relationship remains uncertain.
To limit unwarranted exposure and risks, treatment with diethylpropion hydrochloride extended release tablets, 75 mg should be continued only if the patient has satisfactory weight loss within the first 4 weeks of treatment (e.g., weight loss of at least 4 pounds, or as determined by the physician and patient).
Diethylpropion hydrochloride extended release tablets, 75 mg are not recommended for patients who used any anorectic agents within the prior year.
If tolerance develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued. Diethylpropion hydrochloride extended release tablets, 75 mg may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.
Prolonged use of diethylpropion hydrochloride may induce dependence with withdrawal syndrome on cessation of therapy. Hallucinations have occurred rarely following high doses of the drug. Several cases of toxic psychosis have been reported following the excessive use of the drug and some have been reported in which the recommended dose appears not to have been exceeded. Psychosis abated after the drug was discontinued. When central nervous system active agents are used, consideration must always be given to the possibility of adverse interactions with alcohol.
Because diethylpropion hydrochloride extended release tablets, 75 mg are monoamines, hypertension may result when either agent is used with monoamine oxidase (MAO) inhibitors (See ).
Efficacy of diethylpropion with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems; therefore, the concomitant use with other anorectic agents is contraindicated.
Antidiabetic drug requirements (i.e., insulin) may be altered. Concurrent use with general anesthetics may result in arrhythmias. The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
Caution is to be exercised in prescribing diethylpropion hydrochloride extended release tablets, 75 mg for patients with hypertension or with symptomatic cardiovascular disease, including arrhythmias. Diethylpropion hydrochloride extended release tablets, 75 mg should not be administered to patients with severe hypertension.
Reports suggest that diethylpropion hydrochloride may increase convulsions in some epileptics. Therefore, epileptics receiving diethylpropion hydrochloride extended release tablets, 75 mg should be carefully monitored. Titration of dose or discontinuance of diethylpropion hydrochloride extended release tablets, 75 mg may be necessary.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
Cardiovascular:
Central Nervous System:
Gastrointestinal:
Allergic:
Endocrine:
Hematopoietic System:
Miscellaneous:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).